Session » Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

Date: Sunday, November 7, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0570

A Narrowed, but Persistent Mortality Gap: A National, Matched Cohort Study in U.S. Veterans with Rheumatoid Arthritis from 2000-2017

8:30AM-10:30AM: Abstract Number: 0569

All-Cause and Cause-Specific Mortality in Spondyloarthritis: A Systematic Review and Meta-Analysis

8:30AM-10:30AM: Abstract Number: 0582

Altered Risk of Gout According to Change of Metabolic Parameters in Young Adults

8:30AM-10:30AM: Abstract Number: 0580

Association Between Female Reproductive Factors and Gout: A Nationwide Population-based Cohort Study of 1 Million Postmenopausal Women

8:30AM-10:30AM: Abstract Number: 0590

Association of Lipid Mediator Profiles and Development of Future Incident Inflammatory Arthritis in a High Risk, Anti-citrullinated Protein Antibody Positive Population

8:30AM-10:30AM: Abstract Number: 0564

Associations of Sinusitis, Pharyngitis, and Respiratory Tract Disease Burden with Incident Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0576

Associations of the MUC5B Promoter Variant with Timing of Articular Diagnosis and Interstitial Lung Disease in Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0573

Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111

8:30AM-10:30AM: Abstract Number: 0589

Circulating Adipokines and Risk of Rheumatoid Arthritis in Women

8:30AM-10:30AM: Abstract Number: 0572

Circulating Cytokines and Chemokines Are Associated with the Risk of Incident Cardiovascular Disease in Rheumatoid Arthritis Independent of Conventional Disease Activity Measures

8:30AM-10:30AM: Abstract Number: 0577

Comorbidity Burden as Scored Using the Rheumatic Disease Comorbidity Index (RDCI) Is Associated with Varying Treatment Patterns in Patients with Inflammatory Arthritis – a Study Using the EHR-Derived Rheumatic and Arthritis Disease Information Registry (RADIR)

8:30AM-10:30AM: Abstract Number: 0568

Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)

8:30AM-10:30AM: Abstract Number: 0567

Determinants of Health-Related Quality of Life in Spondyloarthritis and Comparison with Chronic Low Back Pain – Results from a Nation-Wide Study

8:30AM-10:30AM: Abstract Number: 0587

DMARD Use in Medicare Patients with Rheumatoid Arthritis and Risk of Long-Term Opioid Use

8:30AM-10:30AM: Abstract Number: 0588

Effectiveness of TNFi versus Non-TNFi Biologics on Disease Activity in Obese Patients with Rheumatoid Arthritis: Data from the ACR’s RISE Registry

8:30AM-10:30AM: Abstract Number: 0560

Effectiveness, Safety, Quality of Life and Patient Satisfaction with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Second Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study

8:30AM-10:30AM: Abstract Number: 0561

Enhancing the Identification of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Electronic Health Records Through Text Mining of Computerized Tomography Reports

8:30AM-10:30AM: Abstract Number: 0592

Gender Modifies the Effect of Rheumatoid Arthritis on All-Cause Mortality

8:30AM-10:30AM: Abstract Number: 0584

High Number of Comorbidities and Concomitant Medications at Baseline in the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) Study: An Older Population with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0578

Hyperinsulinemic Diet and Increased Risk of Female Gout: 2 Prospective Cohort Studies of US Women over 30 Years

8:30AM-10:30AM: Abstract Number: 0565

Increased Risk for Inflammatory Arthritis in Veterans with Depression or Anxiety

8:30AM-10:30AM: Abstract Number: 0562

Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018

8:30AM-10:30AM: Abstract Number: 0593

Labour Force Participation Among Individuals with Osteoarthritis, Rheumatoid Arthritis/Other Arthritis Types, or with Joint Symptoms but Without a Diagnosis: An Age-Stratified Population-Based Study

8:30AM-10:30AM: Abstract Number: 0566

Natural Language Processing of Electronic Health Record Notes Captures Forced Vital Capacity in Rheumatoid Arthritis-Associated Interstitial Lung Disease

8:30AM-10:30AM: Abstract Number: 0583

Obesity and Lower Socioeconomic Position Are Independently Associated with Incident Osteoarthritis and Rheumatoid Arthritis: Results from the English Longitudinal Study of Ageing

8:30AM-10:30AM: Abstract Number: 0579

Predicting Treatment Change in Rheumatoid Arthritis Patients Treated with TNF Inhibitors as First-Line Biologic Agent

8:30AM-10:30AM: Abstract Number: 0585

Predictors of Health-Related Quality of Life in Rheumatoid Arthritis Patients

8:30AM-10:30AM: Abstract Number: 0574

Prevalence and Early Progression of Lung Diseases in Patients with Recently-Diagnosed Rheumatoid Arthritis: A Prospective Cohort Study

8:30AM-10:30AM: Abstract Number: 0586

Recommended Fiber Intake, but Not Overall Dietary Quality, Is Associated with Reduced Risk of Rheumatoid Arthritis – Results from a Nested Case-control Study

8:30AM-10:30AM: Abstract Number: 0581

Rheumatoid Arthritis Treatment Patterns in Massachusetts: Informative Findings from Insurance Claims Data

8:30AM-10:30AM: Abstract Number: 0571

The National Incidence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2014-2016

8:30AM-10:30AM: Abstract Number: 0591

The Temporal Association Between Hospital Admissions, Disease-modifying Anti-rheumatic Drugs Usage and Direct Health Care Costs in Rheumatoid Arthritis Patients

8:30AM-10:30AM: Abstract Number: 0563

Validating the FRAX Score in a US Population-Based Study of Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0575

World Mortality of Spondyloarthritis and Inflammatory Bowel Diseases in 2015 and Its Evolution Between 2001 and 2015

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].